Lung Cancer Therapeutics Sales are slated to surge at a CAGR of 15.0% during the forecast period 2022-2032 | Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), and Merck Sharp & Dohme Corp
The global Lung Cancer Therapeutics Market was valued at USD 18.3 billion in 2021 and it is anticipated to grow further till USD 74.1 billion by 2031, …